ReviewSmall (Weinheim an der Bergstrasse, Germany)2025
Nucleic Acid-Modified Nanoparticles for Cancer Therapeutic Applications.
Review in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- DNA-Regulated Catalytic-Plasmonic Colocalization Enables Synergistic Signal Amplification in SERS and Nanozyme-Based Sensors.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- A dual-enzyme-like nanozyme adjuvant alleviates tumor hypoxia to enhance photothermally ferroptosis-immune synergistic tumor therapy.Materials today. Bio · 2025Article
- Nucleic Acid-Modified Nanoparticles for Cancer Therapeutic Applications.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Synergestic Protein-Green synthesized Nanoparticles Nanosystems: A Sustainable and Safe Approach for Cancer Theranostics.Nanotheranostics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Nanomaterials including metal or metal oxide nanoparticles, carbonous nanomaterial (e.g., carbon dots) or metal-organic framework nanoparticles provide porous, catalytically active surfaces and functional interfaces for binding of ions or molecular agents. By the conjugation of nucleic acids to the nanoparticles, hybrid nanostructures revealing emerging multimodal catalytic/photocatalytic activities, high loading capacities, and effective targeted cell permeation efficacies are formed. The review article exemplifies the application of nucleic acid-modified nanoparticles conjugates for therapeutic treatment of cancer cells. Stimuli-responsive reconfiguration of nucleic acid strands and the specific recognition and catalytic function of oligonucleotides associated with porous, catalytic, and photocatalytic nanoparticles yield hybrid composites demonstrating cooperative synergistic properties for medical applications. The targeted chemodynamic, photodynamic, photothermal and chemotherapeutic treatment of cancer cells by the oligonucleotide/nanoparticle conjugates is addressed. In addition, the application of oligonucleotide/nanoparticle conjugates for gene therapy treatment of cancer cells is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.